文献速递皮肤肿瘤

淋巴瘤样丘疹病504例相关恶性肿瘤的频率与预后

Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-12-05

该多中心队列研究纳入荷兰皮肤淋巴瘤登记处1985至2018年全部LyP患者504例,中位随访120个月,15.5%伴发血液系统恶性肿瘤(HM),最常见为MF和ALCL;25年随访后HM比例未超过20%。LyP患者非HM风险较一般人群升高(RR 2.8,95%CI 2.4-3.3),应密切监测。

要点

  • LyP患者中15.5%伴发HM,最常见为MF(31例)和ALCL(29例)。
  • 伴发MF或皮肤局限ALCL者预后极佳,但结外ALCL可致死(6/22死亡)。
  • LyP患者非HM风险升高(RR 2.8,95%CI 2.4-3.3),需长期监测。

核心结论

  • LyP患者中15.5%伴发HM,最常见为MF和ALCL,但多数伴发HM者预后极佳。
  • 小部分患者(尤其结外ALCL)可发生侵袭性疾病并死亡。
  • LyP患者非HM风险较一般人群升高(RR 2.8,95%CI 2.4-3.3)。

研究设计与样本

  • 多中心队列研究,纳入荷兰皮肤淋巴瘤登记处1985至2018年全部LyP患者504例。
  • 从中位随访120个月(范围6-585个月),收集每例患者的临床和组织病理学信息。

主要发现

  • 78/504(15.5%)患者伴发HM,最常见为MF(n=31)和ALCL(n=29),19例为其他HM(B细胞14例,髓系5例)。
  • 即使随访25年,伴发HM的比例未超过20%。
  • 78例伴发HM患者中9例死于伴发HM,包括6/22例发生结外ALCL者;伴发MF或皮肤局限ALCL者均预后极佳。
  • 与一般人群相比,LyP患者非HM风险升高(相对风险2.8;95%CI 2.4-3.3),尤其皮肤鳞状细胞癌、黑色素瘤及肠道/肺/膀胱癌。

临床怎么用

  • 临床医生应认识到LyP患者伴发HM及非HM的风险升高,对LyP患者进行密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphomatoid papulosis (LyP) can be associated with other haematological malignancies (HM), but reported percentages vary from 20% to over 50%. OBJECTIVE: To evaluate the frequency and prognostic significance of associated HM and non-HM in LyP patients. METHODS: In this multicentre cohort study, the complete Dutch LyP population was included from the Dutch Cutaneous Lymphoma Registry between 1985 and 2018. Clinical and histopathological information was retrieved from every individual patient. RESULTS: After a median follow-up of 120 months (range, 6-585), an associated HM was observed in 78/504 (15.5%) patients. Most common associated HM were mycosis fungoides (MF; n = 31) and anaplastic large-cell lymphoma (ALCL; n = 29), while 19 patients had another HM of B-cell (n = 14) or myeloid origin (n = 5). Even after a 25-year follow-up period, percentages of associated HM did not exceed 20%. Thirty-nine of 465 patients (8.4%) without a prior or concurrent associated HM developed an associated HM during follow-up, after a median of 68 months (range of 3-286 months). Nine of 78 patients died of associated HM, including 6/22 patients developing extracutaneous ALCL, while all patients with associated MF or skin-limited ALCL had an excellent prognosis. Compared with the general population, LyP patients showed an increased risk (relative risk, 2.8; 95% confidence intervals, 2.4-3.3) for non-HM, in particular cutaneous squamous cell carcinoma, melanoma and intestinal/lung/bladder cancer. CONCLUSIONS: An associated HM was reported in 15.5% of the LyP patients, particularly MF and ALCL. Although the frequency of associated HM is lower than suggested and the prognosis of most patients with associated HM is excellent, a small subgroup will develop aggressive disease, in particular extracutaneous ALCL. Furthermore, LyP patients have a higher risk of developing other malignancies. Clinicians should be aware of these risks, and LyP patients require close monitoring.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Melchers RC, Willemze R, Bekkenk MW, et al. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol. 2019. PMID: 31715046. doi:10.1111/jdv.16065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。